{
  "id": 866503,
  "title": "Helus Pharma Reports First Quarter Fiscal 2027 Financial Results and Recent Business Highlights",
  "url": "https://urgent.news/2026/08/14/helus-pharma-reports-first-quarter-fiscal-2027-financial-results-and",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-14T11:28:35.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/globe-newswire/helus-pharma-reports-first-quarter-fiscal-2027-financial-results-and-recent-business-highlights"
  },
  "original_language": "en",
  "account": null,
  "summary": "– Appointed Michael Halstead, former President of Intra-Cellular Therapies, as Chief Executive Officer to lead Helus Pharma through late-stage development and commercialization – – Completed enrollment in the Phase 3 APPROACH pivotal study of HLP003 in Major Depressive Disorder (“MDD”); topline data remain on track for Q4 20261,2 – – Completed Drug-Drug Interaction (“DDI”) study […]",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}